Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?

Seung Tae Kim, Hae Yun Jung, Jae Sook Sung, Uk Hyun Jo, Tomoaki Tanaka, Koichi Hagiwara, Kyong Hwa Park, Sang Won Shin, Jun Suk Kim, Yeul Hong Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND:: Epidermal growth factor receptor (EGFR) mutations as prognostic or predictive marker in patients with non-small cell lung cancer (NSCLC) have been used widely. However, it may be difficult to get tumor tissue for analyzing the status of EGFR mutation status in large proportion of patients with advanced disease. PATIENTS AND METHODS:: We obtained pairs of tumor and serum samples from 57 patients with advanced NSCLC, between March 2006 and January 2009. EGFR mutation status from tumor samples was analyzed by genomic polymerase chain reaction and direct sequence and EGFR mutation status from serum samples was determined by the peptide nucleic acid locked nucleic acid polymerase chain reaction clamp. RESULTS:: EGFR mutations were detected in the serum samples of 11 patients and in the tumor samples of 12 patients. EGFR mutation status in the serum and tumor samples was consistent in 50 of the 57 pairs (87.7%). There was a high correlation between the mutations detected in serum sample and the mutations detected in the matched tumor sample (correlation index 0.62; P<0.001). Twenty-two of 57 patients (38.5%) received EGFR-tyrosine kinase inhibitors as any line therapy. The response for EGFR-tyrosine kinase inhibitors was significantly associated with EGFR mutations in both tumor samples and serum samples (P<0.05). There was no significant differences in overall survival according to the status of EGFR mutations in both serum and tumor samples (P>0.05). CONCLUSIONS:: Serum sample might be alternatively used in the difficult time of getting tumor tissue for analyzing the status of EGFR mutation status in patients with advanced NSCLC.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume36
Issue number1
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Serum
Neoplasms
Peptide Nucleic Acids
Polymerase Chain Reaction

Keywords

  • EGFR mutation
  • NSCLC
  • serum and tumor samples

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? / Kim, Seung Tae; Jung, Hae Yun; Sung, Jae Sook; Jo, Uk Hyun; Tanaka, Tomoaki; Hagiwara, Koichi; Park, Kyong Hwa; Shin, Sang Won; Kim, Jun Suk; Kim, Yeul Hong.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 36, No. 1, 01.02.2013, p. 57-63.

Research output: Contribution to journalArticle

Kim, Seung Tae ; Jung, Hae Yun ; Sung, Jae Sook ; Jo, Uk Hyun ; Tanaka, Tomoaki ; Hagiwara, Koichi ; Park, Kyong Hwa ; Shin, Sang Won ; Kim, Jun Suk ; Kim, Yeul Hong. / Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2013 ; Vol. 36, No. 1. pp. 57-63.
@article{278a533e1eca42b6bde816045598c342,
title = "Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?",
abstract = "BACKGROUND:: Epidermal growth factor receptor (EGFR) mutations as prognostic or predictive marker in patients with non-small cell lung cancer (NSCLC) have been used widely. However, it may be difficult to get tumor tissue for analyzing the status of EGFR mutation status in large proportion of patients with advanced disease. PATIENTS AND METHODS:: We obtained pairs of tumor and serum samples from 57 patients with advanced NSCLC, between March 2006 and January 2009. EGFR mutation status from tumor samples was analyzed by genomic polymerase chain reaction and direct sequence and EGFR mutation status from serum samples was determined by the peptide nucleic acid locked nucleic acid polymerase chain reaction clamp. RESULTS:: EGFR mutations were detected in the serum samples of 11 patients and in the tumor samples of 12 patients. EGFR mutation status in the serum and tumor samples was consistent in 50 of the 57 pairs (87.7{\%}). There was a high correlation between the mutations detected in serum sample and the mutations detected in the matched tumor sample (correlation index 0.62; P<0.001). Twenty-two of 57 patients (38.5{\%}) received EGFR-tyrosine kinase inhibitors as any line therapy. The response for EGFR-tyrosine kinase inhibitors was significantly associated with EGFR mutations in both tumor samples and serum samples (P<0.05). There was no significant differences in overall survival according to the status of EGFR mutations in both serum and tumor samples (P>0.05). CONCLUSIONS:: Serum sample might be alternatively used in the difficult time of getting tumor tissue for analyzing the status of EGFR mutation status in patients with advanced NSCLC.",
keywords = "EGFR mutation, NSCLC, serum and tumor samples",
author = "Kim, {Seung Tae} and Jung, {Hae Yun} and Sung, {Jae Sook} and Jo, {Uk Hyun} and Tomoaki Tanaka and Koichi Hagiwara and Park, {Kyong Hwa} and Shin, {Sang Won} and Kim, {Jun Suk} and Kim, {Yeul Hong}",
year = "2013",
month = "2",
day = "1",
doi = "10.1097/COC.0b013e31823a5217",
language = "English",
volume = "36",
pages = "57--63",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?

AU - Kim, Seung Tae

AU - Jung, Hae Yun

AU - Sung, Jae Sook

AU - Jo, Uk Hyun

AU - Tanaka, Tomoaki

AU - Hagiwara, Koichi

AU - Park, Kyong Hwa

AU - Shin, Sang Won

AU - Kim, Jun Suk

AU - Kim, Yeul Hong

PY - 2013/2/1

Y1 - 2013/2/1

N2 - BACKGROUND:: Epidermal growth factor receptor (EGFR) mutations as prognostic or predictive marker in patients with non-small cell lung cancer (NSCLC) have been used widely. However, it may be difficult to get tumor tissue for analyzing the status of EGFR mutation status in large proportion of patients with advanced disease. PATIENTS AND METHODS:: We obtained pairs of tumor and serum samples from 57 patients with advanced NSCLC, between March 2006 and January 2009. EGFR mutation status from tumor samples was analyzed by genomic polymerase chain reaction and direct sequence and EGFR mutation status from serum samples was determined by the peptide nucleic acid locked nucleic acid polymerase chain reaction clamp. RESULTS:: EGFR mutations were detected in the serum samples of 11 patients and in the tumor samples of 12 patients. EGFR mutation status in the serum and tumor samples was consistent in 50 of the 57 pairs (87.7%). There was a high correlation between the mutations detected in serum sample and the mutations detected in the matched tumor sample (correlation index 0.62; P<0.001). Twenty-two of 57 patients (38.5%) received EGFR-tyrosine kinase inhibitors as any line therapy. The response for EGFR-tyrosine kinase inhibitors was significantly associated with EGFR mutations in both tumor samples and serum samples (P<0.05). There was no significant differences in overall survival according to the status of EGFR mutations in both serum and tumor samples (P>0.05). CONCLUSIONS:: Serum sample might be alternatively used in the difficult time of getting tumor tissue for analyzing the status of EGFR mutation status in patients with advanced NSCLC.

AB - BACKGROUND:: Epidermal growth factor receptor (EGFR) mutations as prognostic or predictive marker in patients with non-small cell lung cancer (NSCLC) have been used widely. However, it may be difficult to get tumor tissue for analyzing the status of EGFR mutation status in large proportion of patients with advanced disease. PATIENTS AND METHODS:: We obtained pairs of tumor and serum samples from 57 patients with advanced NSCLC, between March 2006 and January 2009. EGFR mutation status from tumor samples was analyzed by genomic polymerase chain reaction and direct sequence and EGFR mutation status from serum samples was determined by the peptide nucleic acid locked nucleic acid polymerase chain reaction clamp. RESULTS:: EGFR mutations were detected in the serum samples of 11 patients and in the tumor samples of 12 patients. EGFR mutation status in the serum and tumor samples was consistent in 50 of the 57 pairs (87.7%). There was a high correlation between the mutations detected in serum sample and the mutations detected in the matched tumor sample (correlation index 0.62; P<0.001). Twenty-two of 57 patients (38.5%) received EGFR-tyrosine kinase inhibitors as any line therapy. The response for EGFR-tyrosine kinase inhibitors was significantly associated with EGFR mutations in both tumor samples and serum samples (P<0.05). There was no significant differences in overall survival according to the status of EGFR mutations in both serum and tumor samples (P>0.05). CONCLUSIONS:: Serum sample might be alternatively used in the difficult time of getting tumor tissue for analyzing the status of EGFR mutation status in patients with advanced NSCLC.

KW - EGFR mutation

KW - NSCLC

KW - serum and tumor samples

UR - http://www.scopus.com/inward/record.url?scp=84872913887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872913887&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e31823a5217

DO - 10.1097/COC.0b013e31823a5217

M3 - Article

C2 - 22237146

AN - SCOPUS:84872913887

VL - 36

SP - 57

EP - 63

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -